CanSino Biologics, Inc.

DUBAI, UAE, Feb. 17, 2025 /PRNewswire/ -- CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai from February 11-13. Dr Yu Xuefeng, Chairman and Chief Executive Officer , along with Ms Wang Jing, Chief Commercial Officer and Executive Director, showcased the Company's pioneering technologies and public health strategies during this prestigious event. Continue Reading The 12th edition of the World Government Summit (WGS 2025) brings together influential leaders, heads of state, and tech visionaries from 140 countries to collaborate on global progress over the next decade. The summit focuses on addressing rapid changes, evaluating humanity's progress, identifying improvement opportunities, and empowering future generations through effective governance and sustainability. CanSinoBIO's participation in the summit represents a significant milestone in its global expansion, highlighting its commitment to global public health. By engaging with global leaders, the Company aims to showcase its growing influence, strengthen its biopharma position, and drive innovation and collaboration for a positive global impact. Driving Global Health Solutions CanSinoBIO positions itself as a global vaccine provider rooted in China, dedicated to offering innovative, high-quality, and affordable vaccines worldwide. Over the past sixteen years, CanSinoBIO has established an industry system that meet international standards, and leveraged five advanced technology platforms to develop dozens of innovative vaccine products targeting over ten infectious diseases. "CanSinoBIO is honored to stand as the exclusive representative of Chinese biotechnology companies at the conference," said Dr. Yu Xuefeng. "Our participation in this global platform underscores our dedication to advancing public health solutions and engaging with our partners worldwide to build a healthier and more sustainable future. Moving forward, we will persist in developing a globally competitive pipeline for novel vaccines, such as inhaled tuberculosis vaccine, PBPV and VLP-Polio vaccine." Enhance Global Partnerships for Improved Global Health CanSinoBIO actively builds global partnerships to boost local vaccine production and reduce vaccine disparities. Since 2019, it has expanded its international presence by strengthening its commercial team, increasing production capacity, and partnering with countries in the Middle East, Southeast Asia, and Latin America. Additionally, Menhycia®, the Company's quadrivalent meningococcal conjugate vaccine, has been granted Halal Decree by the Assessment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia, which is a good reference for the Muslim world. CanSinoBIO has also secured Halal Decree for multiple vaccine products, making vaccines more accessible and affordable for people in the MENA region and beyond. This initiative contributes positively to the global public health system. CanSinoBIO has developed five advanced technological platforms and established a rich portfolio of pipeline products that prevent more than ten diseases, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, Ebola virus disease etc. Additionally, the Company has multiple globally innovative vaccine products in clinical trial stage, such as its protein-based pneumococcal vaccine (PBPV) and recombinant polio vaccine (VLP-Polio). The PBPV is not serotype-dependent and has broader coverage (at lease 98% coverage of pnemococcal strains), highlighting the potential public health value of this vaccine.. Furthermore, VLP-Polio, a non-infectious polio vaccine that does not rely on live viruses, has secured $19 million in project funding from the Bill & Melinda Gates Foundation and is endorsed by the World Health Organization as a preferred vaccine for the future eradication of polio. Moving forward, CanSinoBIO looks forward to continuing its collaboration with global partners to address the challenges posed by infectious diseases, fulfilling its social and international responsibilities, and contributing to the advancement of global public health. SOURCE CanSinoBIO WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

At the World Congress on Lung Cancer in September 2024, Kangfang Biotics released Evoxil monotherapy (PD-1/VEGF bispecial antibody) and Merck Pabolizumab monotherapy in the first-line treatment of PD-L1 expression positive (PD-L1 Key data from a registered Phase III clinical study (HARMONi-2/AK112-303) of locally advanced or metastatic non-small cell lung cancer (NSCLC) with TPS≥1%. Two months later, Merck also introduced a PD-1/VEGF bisspecific antibody: LM-299. In addition to Merck, many well-known pharmaceutical companies have also invested in the field of PD-(L)1 dual antibody. In recent years, there have been frequent deals in this area, with Chinese biotech companies becoming the main transferers. PD-1 and VEGF are often up-regulated and co-expressed in solid tumors. Anti-vegf drugs have synergistic effects with immune checkpoint inhibitors (ICI) in promoting tumor vascular normalization and stimulating immune activation. Kangfang's remarkable achievements in the HARMONi-2 study confirmed that PD-(L)1/VEGF double antibody has the potential to replace PD-1 monoclonal antibody. Eboxizumab is currently approved in China for use in combination with pemetrexed and carboplatin for the treatment of EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC patients who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). A marketing application has also been filed for the first-line treatment of ivoximab in patients with PD-L1 positive (TPS≥1%) NSCLC. Other clinically advanced PD-(L)1/VEGF pipelines are almost all from China, which has triggered a rush to authorize domestic PD-(L)1/VEGF drugs to the sea. However, PD-1 monoclonal antibody still faces problems such as low response rate, safety and drug resistance, so the market is full of expectations for the development of a new generation of immunotherapy. At present, PD-1/VEGF double antibody has been the first to achieve a breakthrough, and we look forward to more exciting progress in this field in the future.

The new facilities fall under the umbrella of MilliporeSigma’s €1 billion investment to advance mRNA technologies and build its global mRNA network. On a €1 billion quest to build a global mRNA network, Merck KGaA’s MilliporeSigma has rounded out its service offerings to include all key stages of mRNA development, manufacturing and commercialization. Tuesday, MilliporeSigma christened two new mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany. The company has invested €28 million in the sites, where it plans to hire 75 new staffers, MilliporeSigma said in a release. The new facilities will be able to tackle a full range of mRNA services, from pre-clinical to commercial-scale projects, MilliporeSigma said. Those offerings will include analytical development and biosafety testing specifically designed for mRNA technologies, the company added. The facilities fall under the umbrella of MilliporeSigma’s €1 billion investment to advance mRNA technologies and build its global mRNA network. Employing 27,000 worldwide, MilliporeSigma sells life sciences companies the tools and tech needed for testing and manufacturing. It also operates a contract testing, development and manufacturing organization to provide services for partners to advance their products. Meanwhile, following mRNA’s breakout success in the COVID-19 pandemic, many companies are pursuing the promising technology. Recently, England’s Centre for Process Innovation (CPI) opened a £26.4 million ($32 million) plant in Darlington, England. The site, called the RNA Centre of Excellence, will support the development and production of RNA products in clinical trials. In early August, China’s CanSino and AstraZeneca inked an mRNA manufacturing deal that’s set to last for at least 10 years. Under the deal, CanSino will use its mRNA manufacturing platform to support AZ on the R&D of certain vaccines.